PROGRESS REPORT 2012 - CLARA
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
PROGRESS REPORT 2012
Contents
EDITORIAL 3
CLARA’S MISSIONS 4
KEY FIGURES 2012 5
STRUCTURING OF RESEARCH 6
> Scientific Animation ....................................................................................................................... 6
UÊ /Ü>À`ÃÊ,iÃi>ÀV Ê«>ÀÌiÀÃ «ÃÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 6
UÊ ÊÊÜÌ ÊÌ iÊ`ÕÃÌÀÞÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 8
> Emerging Axes............................................................................................................................. 10
UÊ Õ>]ÊiVVÊ>`ÊÃV>ÊÃViVið°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 10
UÊ ÛÀiÌ]Ê ÕÌÀÌÊ>`Ê >ViÀÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 12
> Transverse actionsÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 14
> International influence ................................................................................................................. 16
SUPPORTING RESEARCH PROJECTS 18
> Fostering the Emergence of Projects ........................................................................................... 18
UÊ LÌÞÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 18
UÊ "V-Ì>ÀÌiÀ .............................................................................................................................. 19
> CLARA Proof of Concept: Industrial and clinical transfer ................................................................ 20
> Major interregional projects ......................................................................................................... 22
> Financing of interregional projects ............................................................................................... 24
FINANCIAL RESULTS 26
APPENDIX 27
> Financing attributed in 2012 ....................................................................................................... 28
> Financial Tables ............................................................................................................................ 37
CLARA’S COORDINATION TEAM 43
More info on www.canceropole-clara.com
2
Editorial
2012, A NEW
MOMENTUM FOR THE
CANCÉROPÔLE LYON
AUVERGNE RHÔNE-ALPES
As a leading research cluster in supporting the
creation and advancement of large-scale projects in
oncology, the Cancéropôle Lyon Auvergne Rhône-
Alpes (CLARA), has strengthened its commitment,
all through 2012, to the members of its network,
at the institutional level and by the deployment of
its programs.
As CLARA reaches its 10th anniversary and a new Sciences, Environment, Nutrition) by helping them
Cancer Plan is on the horizon, the CLARA executive build strong scientific foundations and tackle the
leadership sought to breathe new energy into the new challenges in the fight against Cancer.
organization and offer fresh perspectives. In an
economic climate requiring that every outlay proves For 2013, CLARA’s path is clear and has four
as cost effective as possible, CLARA had to solidify objectives:
its position to ensure that researchers, clinicians,
and industry professionals in Oncology have the s Transform CLARA into a “Network of Networks
best chance of success and that patients receive in Oncology” to foster dialogue between all
the finest care. stakeholders
Therefore, an Executive Steering Committee was s Offer an interregional scientific strategy that
formed in 2012 to assist CLARA in moving toward integrates basic and clinical research
a “Network of Networks in Oncology”, enhancing
CLARA’s capacity to bring together all the s Address the issue of inequity in our approaches
stakeholders in Clermont-Ferrand, Saint-Étienne, to Cancer by fleshing out the emerging themes
Grenoble and Lyon. in Oncology that are now at the center of patient
lives and cause for societal concern
The year 2012 also saw the development of official
ties with the competitiveness cluster Lyonbiopôle. s Develop closer ties with Lyonbiopôle to improve
The objective is twofold: converge the two the regional innovation ecosystem.
clusters’ methods of fostering the emergence of
innovation and accrediting R&D projects as well as Working together will get us farther down the road
assist in achieving optimal knowledge transfer and to Cancer Research.
exploitation of research results to create clinical
applications.
Given the historic missions of CLARA to lead and
organize Oncology Research, it is now taking a Véronique TRILLET-LENOIR Amaury MARTIN
major step forward in broadening its support of *ÀiÃ`iÌ]Ê -iVÀiÌ>ÀÞÊiiÀ>
emerging themes (Human, Economic and Social >>}iiÌÊ ÌÌii
Progress
P g es Report 2012
20 2
3
CLARA’s Missions
A NETWORK OF NETWORKS
FOR ADVANCING CANCER RESEARCH
Since its creation in 2003 as part of the first Cancer CLARA’S GOALS
Plan, the Cancéropôle Lyon Auvergne Rhône-Alpes
(CLARA) has been uniting and leading a network > Consolidate a network of experts
associating academic, clinical and industrial to accelerate Cancer Research
strengths in Cancer Research in Rhône-Alpes
Auvergne. > Support the clinical development
of innovative projects
Mandated to organize Oncology Research, CLARA
> Reinforce national and international
is one of the key stakeholders involved in innovative
projects that focus on the quick exploitation of collaborative dynamics to increase the
research results for the direct benefit of patients. participation of research teams in ambitious
programs
Supported by the French National Cancer Institute > Fully engage in global Cancer efforts
(INCa) and 14 local authorities, CLARA is working by partnering with Lyonbiopôle with the
to promote interregional strengths on the national support of local authorities
and international stages and contribute to economic
growth in the Rhône-Alpes and Auvergne regions. > Speed up the creation of companies, their
growth, and their interregional establishment
CLARA: Network of Networks in Oncology in Rhône-Alpes and Auvergne
LYON
IARC, CRMN, CRCL, ENS,
HCL, CLB, SIRIC, EMRC, CTD,
RRC Réseau Espace Santé
Cancer Rhône-Alpes, UCBL,
LYONBIOPÔLE, SYNERGIE
LYON CANCER, PARRC-ARA,
CALYM, ELI, WSN, GCS-LCU
CLERMONT-FERRAND
CHU, CJP, RRC
ONCAUVERGNE, UA…
SAINT-ÉTIENNE
CHU, ICL, HYGÉE, GRENOBLE
EMRC, EMSE… IAB, GIN, CHU, CEA,
ESRF, EMRC, UJF,
UPMF, MINALOGIC,
ETOILE, GIRC…
More info on www.canceropole-clara.com
4
Key Figures 2012
CANCER RESEARCH IN
RHÔNE-ALPES AND
AUVERGNE
> M18 received by research teams for
130 projects*
> 1500 active researchers**
> Second region in France in the publication
of scientific papers
s 15% of French publications in Oncology
(Ile-de-France 36%)**
s 20% of leading publications (Top 1%)
(Ile-de-France 45%)** CANCÉROPÔLE LYON
s 17% of high-profile publications (Top 10%)
(Ile-de-France 37%)** AUVERGNE RHÔNE-ALPES
> A network of top researchers with
outstanding results after the INCa 2012 call
for projects, especially in clinical research > Reinforced influence
and emerging themes s 1500 people involved in 31 scientific events
s 23% of projects in the Clinical Cancer s 79 press releases***
Research Hospital Program (PHRC) > Increased support for emerging innovation
s 20% of projects in Human and Social in 2012
Sciences, Epidemiology and Public Health s 425,000 allocated by CLARA to 18 projects*
s 20% of projects in Intervention Research and s 10 OncoStarter* projects to ensure
Reduction of Social Inequalities sustained project development
s 8 mobility grants* to help young researchers
IÊ-iiÊ`iÌ>ÃÊÊ«ÀiVÌÃÊÊÌ iÊ>««i`ÝÊ
IIÊ-ÕÀViÃ\Ê/ ÃÊ,iÕÌiÀÃÊ7-Ê>Õ>ÀÞÊÓä£Ó®ÆÊ LiÌÀVÊ > Proof of Concept program since 2007
>ÞÃÃÊvÊ >ViÀÊ,iÃi>ÀV \ÊÊ >Ì>ÊÌiÀ >VjÀ«iÉ >Ê-ÌÕ`ÞÊ
ÕÞÊÓä£Ó®Êº>VÌÛi»ÊÀiviÀÃÊÌÊ>ÕÌ ÀÊÀÊV>ÕÌ ÀÊvÊ>ÌÊi>ÃÌÊÌ ÀiiÊ s 32 projects supported, 15* in progress and
«ÕLV>ÌÃÊLiÌÜiiÊÓääÈÊ>`ÊÓ䣣® 5 in post-closure follow-up
IIIÊ-ÕÀVi\Ê*ÀiÃÃÊ`iÝÊ«ÀÌÊi`>ÊÞ® s 25,1M invested by interregional business
partners
s 12,2M allocated by local authorities and the
European Regional Development Fund (ERDF)
> Concrete results
s 1 robotic surgical device on the market
s 5 clinical development projects
s 6 preclinical assessments performed
Progress
P g es Report 2012
20 2
5
Structuring of Research
SCIENTIFIC ANIMATION
SCIENTIFIC ANIMATION: AT THE HEART OF CLARA’S
ACTIONS TO CREATE SYNERGIES AND PROMOTE
RESEARCH PARTNERSHIPS
Scientific animation is a top priority for CLARA and
part of an overall strategy of supporting activities
KEY FIGURES 2012
in key themes and stimulating the development
of partnerships between network members and
beyond. > 16 events
> €400,000 annual budget
The events organized or supported in 2012
have made it possible to reinforce interregional > €30,000 allocated to 9 events
interaction, thus enriching the research landscape > 1500 people mobilized
with new projects, new innovations, and many
thematic collaborations.
As a network leader that knows how to mobilize
interregional expertise and assets, CLARA has
directly supported several events. Selected
according to their alignment with the Cancer Plan SPOTLIGHT ON…
priorities, these events offer opportunities for the
7TH SCIENTIFIC FORUM
network to build better targeted relationships and
promote scientific culture.
The flagship CLARA event, the 2012 edition offered:
s Theme day on innovative approaches to combating
Cancer with monoclonal antibodies (partnership
with Lyonbiopôle)
s All-day meeting of interregional actors in Cancer
Research, allowing them to present their ongoing
works and discuss the most recent advances
in basic, clinical and translational research in
thematic sessions, in partnership with national
and international organizations
s Satellite event on Nanomedicine and Oncology
in Rhône-Alpes Auvergne and Catalonia (in
partnership with the Biocat cluster)
Internationally renowned speakers came together
to bring the theme beyond interregional borders
(20% of participants from outside the interregional
area) and allow the development of partnerships in
the study of monoclonal antibodies.
>ViÊ, ,/]Ê iÌiÀÊvÀÊÌ iÊ-ÌÕ`ÞÊvÊ ÀÕ}Ê iÛi«iÌ]Ê
/ÕvÌÃÊ1ÛiÀÃÌÞ]ÊÛÌi`Êëi>iÀÊvÊÌ iÊÇÌ Ê ,Ê-ViÌwVÊÀÕ
More info on www.canceropole-clara.com
6
HIGHLIGHTS 2012
January June
s Open meeting on Nanotechnologies, s Cancer Cells On-Chips: Now and the Future,
Imaging and Cancer - Presentation of projects Lyon y
and networking s Association des Neuro-Oncologues
February d’Expression Française (ANOCEF), [French
s Inter-Cancéropôles conference L>ÃÌ>\ÊÊ association for neuro-oncology and gene
iVÕ>ÀÊ>`Ê iÕ>ÀÊ >À>VÌiÀâ>ÌÊ>`Ê expression], Clermont-Ferrand y
*ÀiVV>Ê `iÃ] Marseille s 8th Annual Forum of the French Sarcoma
March Group – Bone Tumor Study Group, Lyon y
s 7th CLARA Scientific Forum, Lyon September
s 30th meeting of the Club for the Study s 5th Inter-Cancéropôles Bioinformatics
of Epithelial Cells of the Digestive Tract Workshop, Lyon
(CECED), Grenoble y
October
April s 2nd Translational Research Meeting,
s 4th Inter-Cancéropôles Workshop on Gerland Lyon-Sud y
Bioinformatics, Nice
November
May s 12th International Conference on Cancer-
s Workshop on i}À>« V>Ê««À>V iÃÊÌÊ Induced Bone Disease, Lyon y
Û>Õ>Ì}Ê Ý«ÃÕÀiÊÌÊ*iÃÌV`iÃ, Lyonc
s 6th Francophone Conference on Clinical s 2nd Franco-Chinese Symposium on
Epidemiology (EPICLIN) / 19th Statistician Oncology Research, Lyon
Forum of the Centers for the Fight Against December
Cancer, Lyon y s 11th LOWRAD International Conference,
s 3rd edition of Courir Pour Elles, (Women’s Lyon y
Run Against Breast Cancer), Lyon/Domaine de
Lacroix Lavalc
"À}>âiÀÊÀÊVÀ}>âiÀÊ y Õ`} cÃÌÌÕÌ>Ê«>ÀÌiÀ
CLARA’S MISSIONS
Cancerology Community
Reseachers, Industrials, Clinicians... Research Projects in Cancerology
Research
support > Scientific
and Therapeutic
Financing Innovations
for Patients
Interregional
> Territorial
Community Expertise
Animation Economic
and Projects Development
Follow-up
Progress Report 2012
7
Structuring of Research
SCIENTIFIC ANIMATION
SCIENTIFIC ANIMATION RELATED TO DEVELOPMENT:
PROMOTING THE TRANSFER OF RESEARCH RESULTS
TO INDUSTRY AND HEALTHCARE
Entrusted by local authorities to play a key role in
HIGHLIGHTS 2012 stimulating economic growth, CLARA organized
several scientific events in 2012 related to the
April exploitation of research results in order to promote
s Webinar Üi`}iÊ/À>ÃviÀÊ>`Ê Ý«Ì>ÌÊvÊ the transfer of results to industry and patient care.
,iÃi>ÀV Ê,iÃÕÌÃÊÊ"V}Þ\Ê1`iÀÃÌ>`}ÊÌ iÊ
,Ê*ÀvÊvÊ Vi«Ì Whether in the form of webinars, training sessions,
July workshops or meetings, the objective is to expand
s Workshop on Industrial Property and the expertise of the network and help build
Innovation Strategy (Part 1), Lyon * partnerships between industry and academics.
September
s Webinar ,>ÀiÊ >ViÀÃÊ>ÃÊ `iÃÊvÀÊ V>Ê
*ÀvÊvÊ Vi«ÌÊvÀÊÛ>ÌÛiÊ >ViÀÊ
/Ài>ÌiÌÃ
s Educational Session of the CLARA
Regulatory Unit >ViÀÊ6>VViÃ] Lyon
s Workshop on Industrial Property and
Innovation Strategy (Part 2), Lyon *
October
s Education: CLARA-MATWIN Proof of
Concept Training ÌÀ`ÕVÌÊÌÊ ÀÕ}Ê
ÃVÛiÀÞ\ÊÀÊÌ iÊ >LÊÌÊ >ÀÞÊ V>Ê1Ãi,
Lyon
s Workshop on Industrial Property and
Standards]ÊLyon *
November
s Workshop on Protecting Combination
Products in Healthcare: ÌiV }ÞÊ
SPOTLIGHT ON…
ÛiÌÃÊqÊ i`V>Ê iÛViÃ] Lyon * TRAINING SESSION INTRODUCTION
December TO DRUG DISCOVERY: FROM THE
s Workshop on Technology Forecasting and LAB TO EARLY CLINICAL CARE, LYON
Competitive Intelligence in R&D Projects]
Lyon *
s 5th CLARA Industrial/Academic Encounters] Organized by CLARA and MATWIN SAS, this
Lyon training day was specifically addressed to ,Ê
*ÀvÊ vÊ Vi«Ì and /7 2012 project leaders.
"À}>âiÀÊÀÊVÀ}>âiÀ
* *>ÀÌÊvÊÌ iÊ`ÕÃÌÀ>Ê«À«iÀÌÞÊ>Ü>ÀiiÃÃÊ«À}À>ÊÃiÌÊÕ«Ê Intended to meet the needs of academic researchers
LÞÊÌ iÊÀiV Ê >Ì>Ê`ÕÃÌÀÞÊ*À«iÀÌÞÊÃÌÌÕÌiÊ *®]Ê who want to pursue their work continuously until
ÞL«i]Ê >ÀiÊ ÕÃÌiÀÊ>`Ê ,ÊÃiiÊëÌ} ÌÊÊ
«>}iÊ® proof of concept and beyond until transfer to
industry and clinical care, the purpose of this two-
session training program was to raise awareness
of the specific issues and challenges inherent in
development.
More info on www.canceropole-clara.com
8
SPOTLIGHT ON…
KEY FIGURES 2012 WORKSHOPS ON INDUSTRIAL
PROPERTY AWARENESS
> 10 events related to technology
transfer First launched in 2008, CLARA partnered in 2012
> €36,000 annual budget dedicated to with the French National Industry Property Institute
events related to technology transfer (INPI), Lyonbiopôle and I-Care Cluster to organize
workshops on industrial property awareness.
> 400 people mobilized
These workshops are means for any economic
and Research actors concerned with protecting
SPOTLIGHT ON… industrial innovation as a differentiating factor in
5TH CLARA INDUSTRIAL/ACADEMIC competitiveness and growth.
ENCOUNTERS
This key annual event brings together actors in
Oncology Research and development in Rhône- THEY TALKED ABOUT IT…
Alpes and Auvergne. In 2012, the CLARA Industrial/
Academic Encounters offered opportunities for Encounter with Gabriele BARABINO, Jean-
face-to-face meetings between established and Marc PHELIP and Michèle COTTIER, ,Ê
potential partners (like a business convention) as /À« iÃÊÓä£Ó
well as a plenary session on the complementary
strengths of engineering sciences and Oncology, º ,Ê ÃÊ >Ê ÃÌÀ}Ê iiiÌÊ vÊ
underscoring technological and clinical challenges ÌÛ>ÌÊ >`Ê ÃÌÀÕVÌÕÀ}Ê ÜÌ Ê ÕÀÊ
and opportunities. Ìi>Ê >`Ê «ÀiVÌÃÊ >`Ê ÃÊ «ÀÌ>ÌÊ Ê
Special focus was given to the high potential ViVÌ}ÊÕÃÊÌÊÌ iÊÕÌÃ`iÊÜÀ`°
for innovation through a combined approach iÃ`iÃÊ ÕÀÊ ÀiëiVÌÛiÊ >VÌÛÌiÃ]Ê
encompassing engineering and Cancer Research. ,Ê ÃÊ Ì iÊ Ì iÀ ÕÃiÊ vÊ ÕÀÊ
Participants learned of the conclusions reached by a " " " Ê«ÀiVÌ°»
joint CLARA and I-Care Cluster scientific committee
which organized discussions throughout the year
among representatives from medicine, research
and business.
During this event, two high-potential projects
received the CLARA 2012 Trophies:
s Development of Functional Fluorescent
Nanoparticles for Detecting Colorectal
Tumors (G. BARABINO and J.-M. PHELIP,
LINA EA 462 Laboratory / Jean Monnet University,
CHU Saint-Étienne) V miÊ "// ,]Êi> >ÀVÊ* *]Ê>`Ê >}>Ê6 " ]Ê
,Ê/À« iÃÊÓä£Ó
s Transthoracic Therapeutic Imaging Using 3-D
Magnetic Resonance Imaging-Ultrasound Read their complete comments on…
Hybrid Guidance (M. VIALLON, P. CROISILLE www.canceropole-clara.com
and S. SALOMIR, CREATIS, University Hospitals
of Geneva)
/ iÊ ,Ê Ìi>Ê Ì >ÃÊ >Ê Ì iÊ «>ÀÌV«>ÌÃÊ Ê Ì iÊ ÃÌÕ`ÞÊ
}ÀÕ«ÃÊ >ÃÊ ÜiÊ >ÃÊ Ì iÊ iÝ«iÀÌÃÊ Ü Ê >ÌÌi`i`Ê Ì iÊ iÛiÌÃ]Ê
ÃÌÊÌ>LÞÊi>>VµÕiÃÊ< ,Ê>`Ê>VµÕiÃÊ - "/ -°
Progress Report 2012
9
Structuring of Research
EMERGING THEMES
HUMAN, ECONOMIC AND SOCIAL SCIENCES IN
ONCOLOGY: PUTTING PATIENTS AT THE HEART
OF RESEARCH
Recognizing the importance of the human, economic
and social sciences in basic and clinical research,
KEY FIGURES 2012
CLARA supported the expansion of the working
group in 2012 in order to welcome new actors. > 1st French Cancéropôle in Social
To achieve regional and national visibility, several Sciences related to Oncology**
high-priority themes were selected regarding: > 90 researchers**
s Prevention s Healthcare > 20 research teams*
s Social inequalities management
> 15 laboratories evaluated by
s Doctor-patient s Technological AERES, including 9 rated A+ and A*
relationship developments
s Epidemiological > 3 OncoStarter projects launched
indicators in 2012
At the crossroads of the issues of personal risk, > 20% of projects funded by INCa
lifestyle and environmental and community risks in the Human and Social Sciences,
for the individual, the Human, Economic and Social Epidemiology and Public Health are
Sciences focus area of CLARA can spearhead or CLARA projects
advance Research involving basic and applied
disciplines. IÕiÊ Óä£Ó\Ê "ÛiÀÛiÜÊ vÊ Ì iÊ ÌiÀÀi}>Ê `ÀÛ}Ê vÀViÃÊ Ê
, i«iÃÊ ÕÛiÀ}iÊ Ê Õ>Ê >`Ê ÃV>Ê ÃViViÃ]Ê Õ`iÀÊ
Ì iÊÃÕ«iÀÛÃÊvÊ °Ê 8" Ê ,ÊÌiÀ>Ê`>Ì>®
II>Õ>ÀÞÊ Óä£Ó\Ê / ÃÊ ,iÕÌiÀÃÊ 7-ÆÊ ÕÞÊ Óä£Ó\Ê
HIGHLIGHTS 2012 LiÌÀVÊ >ÞÃÃÊ vÊ >ViÀÊ ,iÃi>ÀV \Ê Ê >Ì>Ê ÌiÀ
>VjÀ«iÃÉ >Ê-ÌÕ`Þ
September
Support provided to three new OncoStarter
projects in this area
s 2) 3#/,!)2% aims at implementing intervention
Research on identifying and preventing Cancer in
school environment
s $%$%02/ has set out to adapt, implement and
assess information and decision-support tools for
prostate cancer screening with prostate-specific
antigen testing
s ).%'/ is studying factors contributing to inequa-
lities in initial management of ovarian epithelial
cancer in France between 2011 and 2014
December
Opening of the Hygée Center, a regional Cancer
prevention center and public health platform in
Saint-Étienne
More info on www.canceropole-clara.com
10SPOTLIGHT ON…
HUMAN AND SOCIAL SCIENCES
WORKING GROUPS LED BY INCa
Working group on
Quality of Worklife,
Quality of Care, Patient
Quality of Life
s Promoting and assisting the emergence of
national research projects through open
calls for projects in Human and Social
Sciences, Environment and Public Health
s Helping determine research prospects
in calls for projects in Human and Social
Sciences, Environment and Public Health
INCa Inter-Cancéropôles Working group
on Inequality and Intervention Research
s Helping determine research prospects
in calls for projects in Human and Social
Sciences, Environment and Public Health
s Assisting the completion of national
research projects resulting from calls
for projects
Contact : Véronique REGNIER
Þ}jiÊ iÌiÀ]Ê->ÌÌii®
SPOTLIGHT ON…
HYGÉE: REGIONAL CENTER FOR
First French Cancéropôle in CANCER PREVENTION
scientific publications
The Hygée Center, the CLARA
1,36
regional public health platform,
1,2
is housed in a 2500 square-meter
building near the Loire Cancerology
Institute and is divided into three
CLARA IDF NO PACA GE GSO GO operational divisions:
0,87 s Health education division focused on Cancer
0,82
0,78 prevention activities (primary, secondary and
0,66 tertiary) for the general public
0,57
s Cancer treatment and Research education
ÊÊ-«iV>â>ÌÊ `iÝÊ vÀÊ >VjÀ«iÃÊ Ê «ÕLV>ÌÃÊ Ê division
ÃV>ÊÃViViÃÊ
s Public health Research division to raise regional
ÊÊ6>ÕiÃÊ}Ài>ÌiÀÊÌ >ÊiÊ`V>ÌiÊÌ iÊ >VjÀ«iÊÃÊÀiÊ
ëiV>âi`ÊÊÌ iÊwi`ÊÌ >Ê>ÛiÀ>}iÊÊÀ>Vi awareness of Cancer and Cancer-related issues
This Center represents an investment of €9M,
/ iÊ ,Ê Ìi>Ê Ì >ÃÊ ÕViÌÌiÊ 8" Ê vÀÊ iÀÊ provided by the French government, the Rhône-
Û>Õ>LiÊ «ÕÌÊ Ài}>À`}Ê Ì iÊ Õ>Ê >`Ê ÃV>Ê Alpes Region, the Loire County, Saint-Étienne
ÃViViÃÊvVÕÃÊ>Ài>Ê>`Ê«À«Ã>ÃÊvÀÊiÛÕÌ° Métropole and the Loire Cancerology Institute.
Progress Report 2012
11Structuring of Research
EMERGING THEMES
ENVIRONMENTAL AND NUTRITIONAL FACTORS
IN ONCOLOGY: PROMOTING INTERDISCIPLINARY
RESEARCH THAT ACHIEVES NATIONAL VISIBILITY
In response to the priorities of Cancer Plan II (measure 3),
CLARA has incorporated an Environment, Nutrition
KEY FIGURES 2012
and Cancer focus area into its 2011-2014 program.
Expanded from the thematic focus area Nutrition and
Cancer developed between 2007 and 2010, it aims > 4 OncoStarter projects
to promote interdisciplinary Research in a field that > 3 workshops (pesticides,
has regional and national visibility and to contribute to nanomaterials and nutrition)
improving knowledge of risk factors:
> 3 meetings of the INCa Working
s Environmental (pesticides and nanomaterials) Group
s Nutritional (metabolic mechanisms and
preventive nutrition interventions)
HIGHLIGHTS 2012
SPOTLIGHT ON…
February
INCa WORKING GROUP Launch of the OncoStarter project EXPO-NANO
ON NUTRITION Coordinated by Jean-Michel VERGNON (CHU
Saint-Étienne) and Jérémy POURCHEZ (Saint-
Developing a National Étienne School of Mines), the goal of this
project is to develop an indicator of exposure to
Cancer Nutrition Research
nanoparticles in order to monitor people who are
Network (NACRe) and at occupational risk.
CLARA national expertise in
May
Nutrition and Cancer to: Workshop on Geographical Approaches
to Evaluating Exposure to Pesticides at the
s Promote and assist the emergence of national International Agency for Research on Cancer (IARC)
research projects and Léon Bérard Cancer Center, Lyon
s Help determine research prospects July
Scientific Forum of the Health-Environment
Contact: Marie-Paule VASSON, >VÕÌÞÊvÊ Platform of Rhône-Alpes, EnvitéRA:
Nanomaterials in the Environment and their Impact
* >À>VÞ]Ê1ÛiÀÃÌÞÊvÊÕÛiÀ}i® on the Ecosystem and Human Health
September
Launch of three new OncoStarter projects,
including:
s GEO3N on environmental exposure to dioxins
and the risk of breast cancer
s CASTA on breast cancer and obesity
November
INCa/National Cancer Nutrition Research
Network (NACRe) Nutrition and Cancer Forum
(Before, during, after)
More info on www.canceropole-clara.com
12SPOTLIGHT ON…
RESEARCH CHAIR OF EXCELLENCE
IN ENVIRONMENT, NUTRITION AND
CANCER
In 2010, with the support of the pharmaceutical A public informational web portal on exposure to
company Merck Serono, CLARA awarded the risks related to the environment, workplace and
Chair of Excellence in “Environment, Nutrition and personal behavior was also created. Its objective
Cancer” to Dr Béatrice FERVERS of the Cancer is to provide scientifically sound public health
and Environment Unit of the Léon Bérard Cancer information.
Center. During those three years, Dr FERVERS has
led two major research projects: www.cancer-environnement.fr
s Detecting occupational cancer, in collaboration
with the Consultation Center for Professional
Pathologies, the occupational health center
of the Lyon Civil Hospitals. Aiming to improve
patient education and overall patient care, this
work received the label “Année des patients
et de leurs droits” [year for patients and their
rights] in 2011.
s Study of environmental and nutritional factors
in breast cancer taking two complementary
approaches:
UÊÊ-ÌÕ`ÞÊvÊÌ iÊViÕ>À]ÊLV iV>Ê>`Ê}iVÊ
«>VÌÊvÊV ÀVÊÜ`ÃiÊiÝ«ÃÕÀiÊÌÊÃÕLÃ
Ì>ViÃÊÌ >ÌÊ`ÃÀÕ«ÌÊi`VÀiÊvÕVÌ
UÊÊ,>`âi`Ê VV>Ê ÃÌÕ`ÞÊ vÊ Ì iÊ V >}}Ê
iÌ>LVÊ>`ÊVÞÌiÊ«ÀwiÃÊÊÜiÊ`>
}Ãi`Ê ÜÌ Ê LÀi>ÃÌÊ V>ViÀÊ «>ÀÌV«>Ì}Ê Ê >Ê
ÃÝÌ ÊÕÌÀÌÊ«À}À>Ê`iÌÊ>`ÊiÝiÀVÃi®Ê
VVÌ>ÌÊÜÌ ÊV>ViÀÊÌÀi>ÌiÌ
Progress Report 2012
13Structuring of Research
TRANSVERSE ACTIONS: COMBINING THE
PROACTIVE INTERREGIONAL ACTIONS OF RHÔNE-
ALPES AUVERGNE WITH A NATIONAL APPROACH
CONSISTENT WITH OTHER NETWORKS
Eager to incorporate its actions into a national
approach that includes interregional teams, CLARA
KEY FIGURES 2012
is actively participating in national INCa working
groups and creating close ties with partner
networks by embracing their initiatives.
> 23% of funding for Hospital Clinical
Research Program (PHRC)
on Cancer projects in 2012 are
VIRTUAL MICROSCOPY CLARA projects
> 160 participants in two inter-
Inter-Cancéropôles Working group aiming to: Cancéropôles Bioinformatics
s Share information and know-how for cross- workshops
fertilization between Research-Clinical Care-
Education approaches > 16 meetings of national INCa
Working groups
s Issue recommendations that could become INCa
recommendations > 220 participants in the EPICLIN
s Offer an international organization that works with conference supported by CLARA
business
Contact: David MEYRONET 1Ê Þ®
BIOINFORMATICS
Organizing top-tier inter-
Cancéropôles scientific
animation around the
Bioinformatics platform of the Synergy Lyon Cancer
Foundation and as part of the International Cancer
Genome Consortium.
The themes covered in 2012 in the half-yearly
workshops were:
s New generations of sequencing applied to
Cancer transcriptomics
s High-throughput epigenomics
Contact: Gilles THOMAS 1 ]Ê -ÞiÀ}ÞÊ ÞÊ
>ViÀÊÕ`>Ì]Ê ®
More info on www.canceropole-clara.com
14Photo : Romain ÉTIENNE / ITEM / Fondation
Synergie Lyon Cancer
CLINICAL RESEARCH HIGHLIGHTS 2012
Putting the Clinical Cancer April
4th Inter-Cancéropôles Bioinformatics
Research Support Platform
Workshop, Nice
of the Auvergne Rhône-
Alpes (PARCC-ARA) region at May
19th Statistician Forum of the Centers for the
the center of the activities of Fight Against Cancer and 6th Francophone
the INCa working group to: Conference on Clinical Epidemiology (EPICLIN),
Lyon
s Increase the potential of clinical Cancer Research
September
by helping investigators design, coordinate and
5th Inter-Cancéropôles Bioinformatics
analyze their clinical studies Workshop, Lyon
s Improve INCa clinical trials registry data
s Guide actors involved in local clinical research on
clinical trials
s Identify what determines the supply, demand,
needs and conduct of Cancer clinical trials, espe-
cially when they are associated with inequalities
Contact: David PEROL ]Ê , ]Ê*, ,®
Progress Report 2012
15Structuring of Research
INTERNATIONAL: POSITIONING THE RHÔNE-ALPES AND
AUVERGNE REGIONS AS EUROPEAN REFERENCE SITES
IN THE FIGHT AGAINST CANCER
Aware of the importance of expanding interregional
Research beyond borders, CLARA is actively
KEY FIGURES 2012
promoting international collaborations through
two close partnerships:
> 20 European projects in progress,
s With Spanish Cancer Research clusters representing a budget of close to
(Catalonia and Castilla y Léon) €100M
s Between authorities in Shanghai and the Rhône- > 2 strong collaborations:
Alpes Region. Shanghai and Spanish clusters
> 1 student (Master 2 (Bologna
Process), then Ph.D. thesis) pursuing
IN THEIR WORDS… a joint University of Lyon/Shanghai
University degree
Encounter with Dr Véronique MAGUER-SATTA,
," / Ê«ÀiVÌ
º ,Ê >ÃÊÃÕ««ÀÌi`ÊÕÃÊ>ÌÊiÛiÀÞÊÃÌ>}iÊ
vÊ Ì ÃÊ ÌiÀ>Ì>Ê «ÀiVÌ]Ê Ü V Ê
ÜÕ`Ê ÌÊ iÝÃÌÊ ÜÌ ÕÌÊ Ì°Ê Ê >Ê ÜÀ`]Ê
,Ê>Üi`ÊÕÃÊÌÊ >ÛiÊ>ÊÛû
HIGHLIGHTS 2012
January
Biotecyl cluster’s visit to CLARA: Launch of a
French-Spanish, inter-cluster collaboration
March
Satellite event of the 7th Scientific Forum on
Nanomedicine and Oncology in Rhône-Alpes
Auvergne and Catalonia, in partnership with the
Biocat cluster
6jÀµÕiÊ 1 ,-//Ê>`Ê iÀÊÌi>
November
2nd Franco-Chinese Symposium on Cancer
Read Dr Maguer-Satta’s complete comments at Research, in partnership with the Rhône-Alpes
www.canceropole-clara.com Region
More info on www.canceropole-clara.com
16SPOTLIGHT ON… SPOTLIGHT ON…
COLLABORATION WITH SPANISH 2ND FRANCO-CHINESE SYMPOSIUM ON
ONCOLOGY CLUSTERS CANCER RESEARCH
In an effort to give a prominent European dimen- Since 2011 and thanks to the
sion to the Rhône-Alpes Auvergne interregional support of the Rhône-Alpes
Oncology cooperation, two firm partnerships were Region, CLARA is leading an ambitious program of
forged in 2012 with the Biotecyl and Biocat Spanish collaboration between academic teams in the region
clusters. and their counterparts in Shanghai.
The visit of a French delegation to Shanghai in July
The collaboration with the Biotecyl
2011 resulted in the first collaboration, which focuses
cluster (Salamanca, Castilla y Léon) is
on stem cells (breast and prostate cancer), between
developing a joint work plan whose
Prof GAO (Med-X Renji Hospital, Stem Cell Research
areas of Research relate to new
Center) and Dr MAGUER-SATTA (Cancer Research
therapeutic approaches, personalized medicine
Center of Lyon).
and biomarkers in sarcomas and leukemia. CLARA
invited the Spanish Research leaders to visit Lyon To increase momentum, a delegation of Chinese
in January to prepare an application for an researchers and institutional representatives was
Interreg program. received in Lyon in November 2012. The goal was to
improve mutual understanding of the two countries’
As part of the 7th CLARA Scientific
approaches to the management of Cancer Research
Forum, a satellite event was organized
and care, present the results of the first joint projects
with the Biocat cluster (Catalonia)
and initiate and strengthen collaborative efforts.
on Nanomedicine and Oncology
in Rhône-Alpes Auvergne and Catalonia. Ten Several partnerships are now being set up.
researchers, clinicians and CEOs were invited to
share their activities with regional actors in order to
develop partnerships.
Progress Report 2012
17Supporting Research Projects
FOSTERING THE EMERGENCE OF PROJECTS
MOBILITY: BUILDING TOMORROW’S TALENT
Mobility for young
researchers is a source EXAMPLES OF 2012 PROJECTS
of acquiring new tech-
niques and knowledge > Étude des instabilités génétiques des dysplasies
and promotes the emergence and strengthening of pré-cancéreuses tubo-ovariennes chez les
collaborative projects. For this reason, CLARA set up patientes à risque génétique (Jean Perrin
Cancer Center, Clermont-Ferrand Î
a program in 2011 focusing on mobility. Montreal University Hospital, Canada)
Intended for young researchers in Rhône-Alpes > Étude de la Caséine Kinase 2 et de ses
Auvergne involved in Oncology projects requiring inhibiteurs ; cytotoxicité vis-à-vis de cellules
tumorales pancréatiques (Claude Bernard Lyon
regional, national or international travel lasting
1 University Î CEA of Grenoble)
between one and three weeks, the CLARA Mobility
program can assist with funding up to €2,500. > Impact des expositions environnementales
prénatales sur l’incidence du cancer du testicule
(IARC Î Danish Cancer Society, Karolinska
Institute, Sweden)
/ iÊV«iÌiÊÃÌÊvÊ«ÀiVÌÃÊ>««i>ÀÃÊÊÌ iÊ
>««i`ViÃÊÃiiÊ«°ÊÓn®
KEY FIGURES 2012
> €20,000 allocated
> 8 grants for Mobility
Geographic Origin of Selected Destination of Selected Mobility Projects
Mobility Projects
38%
International
13% 37%
Clermont-Ferrand Within
CLARA
Perimeter
87% 25%
Lyon National
More info on www.canceropole-clara.com
18KEY FIGURES 2012
FOSTERING THE EMERGENCE OF PROJECTS
> €405,000 allllocated
ONCOSTARTER: > 8 projects chosen
SUPPORTING THE s 3 projects in Translational Research
EMERGENCE OF s 5 projects in Environment,
Nutrition, and Human and Social
INNOVATIVE PROJECTS Sciences
Since 2011, thanks
to its unique
position allowing
it to speed up
EXAMPLES OF 2012 PROJECTS
project deve-
Translational Research
lopment to maximize chances of receiving later
> Potentialisation des traitements des cancers du
funding, OncoStarter complements traditional pancréas
project development systems as well as, among > Nouveau marqueur pronostic et prédictif du
others, ,Ê *ÀvÊ vÊ Vi«ÌÊ and INCa calls cancer du sein ER+
for projects. > Développement de nanoparticules fluores-
centes pour la détection des lésions tumorales
In addition to financial assistance allocated colorectales
to solidify scientific data, teams can receive
Emerging Themes
personalized coaching to raise the level of quality
> Représentations et prévention des cancers
of their projects (extension of partnerships, market en milieu scolaire
research, consideration of regulatory issues, etc.).
> Évaluation d’outils d’information et d’aide
Open to all Translational Research projects as well à la décision dans le dépistage du cancer de
la prostate
as those that fall within emerging themes identified
> Facteurs d’inégalités de la prise en charge
by CLARA (Assessment, Perception of Risks initiale des cancers épithéliaux ovariens
and Cancer Prevention, Environment, Nutrition > Vers un indicateur d’exposition aux nanoparticules
and Cancer), it promotes the development of > Expositions environnementales aux dioxines
multidisciplinary approaches. et risque de cancer du sein
/ iÊV«iÌiÊÃÌÊvÊ«ÀiVÌÃÊ>««i>ÀÃÊÊÌ iÊ>««i
`ViÃÊÃiiÊ«°ÊÓn®
In 2012, top priority was given to supporting
projects on emerging themes: Environment,
Nutrition, Human and Social Sciences
Balanced location-based projects
1%
Grenoble
30% 3%
Saint-Étienne
Translational
Research
70%
Emerging 5% 1%
Lyon Clermont-Ferrand
Themes
Progress Report 2012
19Supporting Research Projects
CLARA PROOF OF CONCEPT: A KEY STEP IN REACHING
CLINICAL CARE FASTER
Since 2005, CLARA has been running a unique and
powerful program for exploitation of research results:
KEY FIGURES 2012
the *ÀvÊvÊ Vi«ÌÊ«À}À>°Ê
Through financial support and assistance to academic > 1 robotic surgical device on the
and clinical teams in Rhône-Alpes Auvergne, this market
program makes it easier to develop preclinical
projects and clinical studies on high-potential product > 5 projects in clinical development
candidates (drugs and devices) and generate industrial > 6 preclinical assessments
property to support them. performed
> 32 projects supported, including
15 in progress and 5 in post-project
follow-up**
> €37,3 M overall budget
(€25,1M invested by interregional
business partners and €12,2M by
local authorities and ERDF)
> More than 70 partners, including
7 clinical centers
> 41 scientific publications*
> 43 scientific press releases*
> 25 patent applications*
* >Ãi`ÊÊ`>Ì>Ê>Û>>LiÊÊ iViLiÀÊΣ]ÊÓä£Ó
**Ê*ÀiVÌÃÊ>ÀiÊ`iÃVÀLi`ÊÊÌ iÊ>««i`ÝÊÃiiÊ«°ÊÓ®
In partnership with a company working within
CLARA’s scope of activities that is conducting and
committed to exploiting the research results in the
long run, the program focuses on local economic
growth and contributes to promoting innovative
therapeutic and diagnostic solutions that directly
benefit patients.
More info on www.canceropole-clara.com
20HIGHLIGHTS 2012
January
Synfrizz launches its phase 1 clinical trial first in
man/first in class to develop a new treatment for
synovial sarcoma. Based on an innovative treatment
combining anti-FZD10 antibody with radiation therapy, it
is the first targeted treatment in the world for this type of
Cancer. The trial will take place for 24 months and involve
21 sarcoma patients in three French Cancer centers.
May
Creation of Anastom Surgical as part of the UroLink
project. Led by Arnold FERLIN, the company Anastom A vast field of application of proofs of concept
Surgical is the business partner in the UroLink project targeted since 2005
whose goal is to develop automated urethrovesical
anastomosis for prostate cancer. Spawned from the 12%
technology incubator CREALYS, Anastom Surgical is the Radiotherapy
2012 laureate of the 13th Tremplin Entreprise [Business 28%
Springboard] co-organized by the French Senate and ESEC. Immonotherapy,
12% Biomolecule
June Chimiotherapy
The Enki-HEH project starts clinical trials at the
Lyon Civil Hospitals to test a new tumor resection 3%
technique that uses a pulsed jet of water. Cellular
Therapy
July
A study of high-intensity focused ultrasound 9%
Medical Imaging
(HIFU) begins the phase 2b clinical trial stage for 24%
Medical / Surgical
the treatment of hepatic metastases. Launched in
12% Device
2011, phase 2a clinical trials were approved in February Diagnostic Tool
2012 by a committee of experts. The approvals for
moving to phase 2b by the institutional review board
(CPP) and French Agency for Health Product Safety
(ANSM) were granted in summer 2012. The first three
patients were enrolled in September 2012. Targeted pathologies within the Proof of
The procedures for obtaining CE marking were Concept program since 2005
initiated in December 2012. 3 major indications : breast (17%), liver (12%) and
August brain tumors (12%)
GeniusVac-Mel4 requests approval of a phase
7%
1 clinical trial. The objective of the project is to develop Multiple 2%
an innovative drug treatment (cell therapy) for melanoma. 7% ENT
After receiving a positive response from CPP in October Lymphoma 17%
Breast
2012, feedback from ANSM is expected in 2013. 7%
Sarcoma
September
Reception of nine letters of intent as part of the 3%
8th CLARA Proof of Concept call for projects (six Stomach
12%
Liver
applications assessed) 3%
Oesophagus
November
HepatoFluo received approval to start its phase 1 5%
Colorectal
clinical trial. Based on Fluobeam™ technology from 12%
3% Brain
the company Fluoptics, the objective of the HepatoFluo Kidney
project is to assess the feasibility and effectiveness of a 5% 10%
Prostate Lung
fluorescent marker in improving surgical procedures for 7%
Skin
hepatic metastases and primary liver cancer. Patient en-
rolment will begin in January 2013. The device received
CE marking in December 2012.
/ iÊ ,Ê Ìi>Ê Ì >ÃÊ >Ê Ì iÊ iÝ«iÀÌÃÊ Lâi`Ê Ê Ì iÊ
/ iÊV«iÌiÊÃÌÊvÊ«ÀiVÌÃÊ>««i>ÀÃÊÊÌ iÊ>««i`Við ÃiiVÌÊ >`Ê Ê Ì iÊ vÜÕ«Ê vÊ «ÀiVÌÃ]Ê ÃÌÊ Ì>LÞÊ
i>>VµÕiÃÊ< ,Ê>`Ê V iÊ" 6 /°
Progress Report 2012
21Supporting Research Projects
MAJOR INTERREGIONAL PROJECTS: ENHANCING THE
REPUTATION OF THE TERRITORY IN ONCOLOGY
Emphasizing the importance of making sure that ELI
interregional research teams join forces in innovative EUROPEAN LYMPHOMA INSTITUTE
and competitive projects that address national
Cancer Research priorities and favorably position
Uniting the most prominent
interregional teams in Europe, CLARA and local
lymphoma specialists in Europe in
authorities have partnered since 2009 to implement
an institute dedicated to Research,
a strategy of providing maximum support to
training and education, ELI’s goal is to determine a
development projects.
strategy, therapeutic and diagnostic standards and
Sponsor of leading cooperative groups, such as facilitate basic and clinical Research in Europe.
the European Lymphoma Institute (ELI) and World
Using this one-of-a-kind collaborative operating
Sarcoma Network (WSN), CLARA decided this year
model, ELI wants to advance lymphoma Research
to fund a chair of excellence in Translational Research
to offer all patients equal access to the best care.
in Oncology in Grenoble.
Contact: Bertrand COIFFIER 1Ê Þ®
CHAIR OF EXCELLENCE IN
TRANSLATIONAL RESEARCH IN
ONCOLOGY IN GRENOBLE Lymphoma: 6th Highest Incidence of Cancer in
the World
In 2012, CLARA, CHU Grenoble, Joseph Fourier 3%
3% Kidney
University, Isère County, Grenoble Alpes Métropole Bladder
3%
and the City of Grenoble co-funded a chair of 3% Pancreas
Lymphoma
excellence in Translational Research.
3% 30%
Lip, Oral Cavity, Others
Associated with the creation of a laboratory and Pharynx
dedicated team at the Albert Bonniot Institute, 11%
Lung
this chair of excellence aims to mobilize the
driving forces in Grenoble to collaborate with
pharmaceutical companies to develop innovative
11%
applications. Colon-Rectum
19%
Contact: Christian BRAMBILLA LiÀÌÊ ÌÊ 15% Prostate
Breast
ÃÌÌÕÌi]ÊÀiLi®
Source : >Ê-ÌÕ>ÌÊ`ÕÊ >ViÀÊiÊÀ>ViÊiÊÓä£Ó
More info on www.canceropole-clara.com
22You can also read
